Literature DB >> 28523184

PD-1 targeted Immunotherapy as first-line therapy for advanced non-small-cell lung cancer patients.

Arik Bernard Schulze1, Lars Henning Schmidt1.   

Abstract

Entities:  

Year:  2017        PMID： 28523184      PMCID： PMC5418249          DOI： 10.21037/jtd.2017.03.118

Source DB:  PubMed          Journal:  J Thorac Dis        ISSN： 2072-1439            Impact factor:   2.895


× No keyword cloud information.
  16 in total

1.  B7-H1 is a ubiquitous antiapoptotic receptor on cancer cells.

Authors:  Takeshi Azuma; Sheng Yao; Gefeng Zhu; Andrew S Flies; Sarah J Flies; Lieping Chen
Journal:  Blood       Date:  2008-01-25       Impact factor: 22.113

2.  Nivolumab in Combination With Platinum-Based Doublet Chemotherapy for First-Line Treatment of Advanced Non-Small-Cell Lung Cancer.

Authors:  Naiyer A Rizvi; Matthew D Hellmann; Julie R Brahmer; Rosalyn A Juergens; Hossein Borghaei; Scott Gettinger; Laura Q Chow; David E Gerber; Scott A Laurie; Jonathan W Goldman; Frances A Shepherd; Allen C Chen; Yun Shen; Faith E Nathan; Christopher T Harbison; Scott Antonia
Journal:  J Clin Oncol       Date:  2016-06-27       Impact factor: 44.544

3.  Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial.

Authors:  Roy S Herbst; Paul Baas; Dong-Wan Kim; Enriqueta Felip; José L Pérez-Gracia; Ji-Youn Han; Julian Molina; Joo-Hang Kim; Catherine Dubos Arvis; Myung-Ju Ahn; Margarita Majem; Mary J Fidler; Gilberto de Castro; Marcelo Garrido; Gregory M Lubiniecki; Yue Shentu; Ellie Im; Marisa Dolled-Filhart; Edward B Garon
Journal:  Lancet       Date:  2015-12-19       Impact factor: 79.321

4.  Loss of tumor suppressor PTEN function increases B7-H1 expression and immunoresistance in glioma.

Authors:  Andrew T Parsa; James S Waldron; Amith Panner; Courtney A Crane; Ian F Parney; Jeffrey J Barry; Kristine E Cachola; Joseph C Murray; Tarik Tihan; Michael C Jensen; Paul S Mischel; David Stokoe; Russell O Pieper
Journal:  Nat Med       Date:  2006-12-10       Impact factor: 53.440

5.  Upregulation of PD-L1 by EGFR Activation Mediates the Immune Escape in EGFR-Driven NSCLC: Implication for Optional Immune Targeted Therapy for NSCLC Patients with EGFR Mutation.

Authors:  Nan Chen; Wenfeng Fang; Jianhua Zhan; Shaodong Hong; Yanna Tang; Shiyang Kang; Yaxiong Zhang; Xiaobo He; Ting Zhou; Tao Qin; Yan Huang; Xianping Yi; Li Zhang
Journal:  J Thorac Oncol       Date:  2015-06       Impact factor: 15.609

6.  Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer.

Authors:  Martin Reck; Delvys Rodríguez-Abreu; Andrew G Robinson; Rina Hui; Tibor Csőszi; Andrea Fülöp; Maya Gottfried; Nir Peled; Ali Tafreshi; Sinead Cuffe; Mary O'Brien; Suman Rao; Katsuyuki Hotta; Melanie A Leiby; Gregory M Lubiniecki; Yue Shentu; Reshma Rangwala; Julie R Brahmer
Journal:  N Engl J Med       Date:  2016-10-08       Impact factor: 91.245

7.  Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer.

Authors:  Hossein Borghaei; Luis Paz-Ares; Leora Horn; David R Spigel; Martin Steins; Neal E Ready; Laura Q Chow; Everett E Vokes; Enriqueta Felip; Esther Holgado; Fabrice Barlesi; Martin Kohlhäufl; Oscar Arrieta; Marco Angelo Burgio; Jérôme Fayette; Hervé Lena; Elena Poddubskaya; David E Gerber; Scott N Gettinger; Charles M Rudin; Naiyer Rizvi; Lucio Crinò; George R Blumenschein; Scott J Antonia; Cécile Dorange; Christopher T Harbison; Friedrich Graf Finckenstein; Julie R Brahmer
Journal:  N Engl J Med       Date:  2015-09-27       Impact factor: 91.245

8.  Enhancement of antitumor immunity by CTLA-4 blockade.

Authors:  D R Leach; M F Krummel; J P Allison
Journal:  Science       Date:  1996-03-22       Impact factor: 47.728

9.  PD-L1 Is Upregulated by Simultaneous Amplification of the PD-L1 and JAK2 Genes in Non-Small Cell Lung Cancer.

Authors:  Seiichi Ikeda; Tatsuro Okamoto; Shinji Okano; Yuichiro Umemoto; Tetsuzo Tagawa; Yosuke Morodomi; Mikihiro Kohno; Shinichiro Shimamatsu; Hirokazu Kitahara; Yuzo Suzuki; Takatoshi Fujishita; Yoshihiko Maehara
Journal:  J Thorac Oncol       Date:  2016-01       Impact factor: 15.609

Review 10.  Novel therapeutic targets on the horizon for lung cancer.

Authors:  Wan-Ling Tan; Amit Jain; Angela Takano; Evan W Newell; N Gopalakrishna Iyer; Wan-Teck Lim; Eng-Huat Tan; Weiwei Zhai; Axel M Hillmer; Wai-Leong Tam; Daniel S W Tan
Journal:  Lancet Oncol       Date:  2016-08       Impact factor: 41.316
View more
  9 in total

Review 1.  Combining radiation plus immunotherapy to improve systemic immune response.

Authors:  Taylor R Cushman; Daniel Gomez; Rachit Kumar; Anna Likacheva; Joe Y Chang; Alex P Cadena; Sebastien Paris; James W Welsh
Journal:  J Thorac Dis       Date:  2018-02       Impact factor: 2.895

2.  Systematic analysis of the transcriptome in small-cell carcinoma of the oesophagus reveals its immune microenvironment.

Authors:  Qi Zhao; Yan-Xing Chen; Qi-Nian Wu; Chao Zhang; Min Liu; Ying-Nan Wang; Yan-Fen Feng; Jia-Jia Hu; Jian-Hua Fu; Hong Yang; Jing-Jing Qi; Zi-Xian Wang; Yun-Xin Lu; Hui Sheng; Ze-Xian Liu; Zhi-Xiang Zuo; Jian Zheng; Jing-Ping Yun; Jin-Xin Bei; Wei-Hua Jia; Dong-Xin Lin; Rui-Hua Xu; Feng Wang
Journal:  Clin Transl Immunology       Date:  2020-10-05

Review 3.  CAR-T Therapy for Pediatric High-Grade Gliomas: Peculiarities, Current Investigations and Future Strategies.

Authors:  Laura Antonucci; Gabriele Canciani; Angela Mastronuzzi; Andrea Carai; Giada Del Baldo; Francesca Del Bufalo
Journal:  Front Immunol       Date:  2022-05-04       Impact factor: 8.786

4.  Interval between planning and frameless stereotactic radiosurgery for brain metastases: are our margins still accurate?

Authors:  Charlotte Bronnimann; Aymeri Huchet; Julie Benech-Faure; Caroline Dutriaux; Olivier Saut; Eivind Blais; Olivier Mollier; Renaud Trouette; Veronique Vendrely
Journal:  Neurooncol Pract       Date:  2019-10-01

Review 5.  Next Generation CAR T Cells for the Immunotherapy of High-Grade Glioma.

Authors:  Christopher T Petersen; Giedre Krenciute
Journal:  Front Oncol       Date:  2019-02-26       Impact factor: 6.244

Review 6.  SARS-COV-2 infection and lung tumor microenvironment.

Authors:  Naila Malkani; Muhammad Usman Rashid
Journal:  Mol Biol Rep       Date:  2021-01-23       Impact factor: 2.316

7.  Tumor infiltrating T cells influence prognosis in stage I-III non-small cell lung cancer.

Authors:  Arik Bernard Schulze; Georg Evers; Dennis Görlich; Michael Mohr; Alessandro Marra; Ludger Hillejan; Jan Rehkämper; Lars Henning Schmidt; Birthe Heitkötter
Journal:  J Thorac Dis       Date:  2020-05       Impact factor: 3.005

Review 8.  Clinical Application of iNKT Cell-mediated Anti-tumor Activity Against Lung Cancer and Head and Neck Cancer.

Authors:  Mariko Takami; Fumie Ihara; Shinichiro Motohashi
Journal:  Front Immunol       Date:  2018-09-07       Impact factor: 7.561

Review 9.  Regulatory B cells in respiratory health and diseases.

Authors:  Madhvi Menon; Tracy Hussell; Halima Ali Shuwa
Journal:  Immunol Rev       Date:  2021-01-06       Impact factor: 10.983
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.